Galileo Genomics Inc., based in Montreal, Quebec, Canada, is a genetic research company focused on discovering true disease genes that unequivocally cause common and complex diseases. By identifying these genes, Galileo aims to develop gene-validated targets that can lead to more effective drug therapies and diagnostics, addressing the root causes of diseases rather than just the symptoms. The company has a proven track record in disease gene discovery, with successful examples in conditions such as schizophrenia and multiple sclerosis. Galileo leverages founder populations, which have a relatively homogeneous gene pool, to link genes with the diseases they cause. The company is building a Biobank of DNA and other tissue samples from the Quebec population to facilitate this discovery process. Galileo seeks partnerships with biopharmaceutical companies to develop therapies based on these disease genes and to share the risk involved in the discovery process. The business model revolves around forming strategic alliances for early-stage gene discovery and collaborating with partners to bring new therapies to market. Revenue is generated through these partnerships and the development of proprietary genetic research tools and diagnostics.

Keywords: genetic research, disease genes, drug therapies, diagnostics, gene discovery, biobank, founder populations, biopharmaceutical partnerships, Montreal, Quebec